Hotchkis & Wiley Capital Management LLC Trims Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Hotchkis & Wiley Capital Management LLC reduced its holdings in Jazz Pharmaceuticals by 28.4%, now owning 29,740 shares worth approximately $3.69 million as of the latest SEC filing.
• Jazz Pharmaceuticals reported a quarterly EPS of -$8.25, which missed analysts' expectations and represents a significant drop from the previous year's EPS of $5.30.
• Analysts have set a new average price target of $181.43 for Jazz Pharmaceuticals, with most ratings currently classified as a "Moderate Buy."

Hotchkis & Wiley Capital Management LLC lessened its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 28.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 29,740 shares of the specialty pharmaceutical company's stock after selling 11,775 shares during the quarter. Hotchkis & Wiley Capital Management LLC's holdings in Jazz Pharmaceuticals were worth $3,692,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. Nuveen LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter valued at $62,362,000. Darwin Global Management Ltd. purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $59,668,000. Fuller & Thaler Asset Management Inc. raised its stake in Jazz Pharmaceuticals by 41.7% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after purchasing an additional 391,660 shares during the period. Perpetual Ltd raised its stake in Jazz Pharmaceuticals by 60.2% during the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after purchasing an additional 357,784 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after purchasing an additional 315,608 shares during the period. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. The Goldman Sachs Group boosted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a "buy" rating in a report on Friday. Piper Sandler restated an "overweight" rating and set a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $178.67.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the sale, the chief executive officer directly owned 436,973 shares of the company's stock, valued at approximately $47,031,403.99. This represents a 0.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $1.62 during trading hours on Friday, reaching $127.75. The company's stock had a trading volume of 675,563 shares, compared to its average volume of 900,719. The stock has a market cap of $7.75 billion, a PE ratio of -18.98, a PEG ratio of 7.95 and a beta of 0.34. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company's 50-day moving average is $114.48 and its two-hundred day moving average is $117.23. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals's revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the company posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.